Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 4Terminated 3Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 5Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Hairy Cell 2Hodgkin Disease 2Waldenstrom Macroglobulinemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Hematopoietic and Lymphoid System Neoplasm 1Classic Follicular Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 22Lenalidomide 13orelabrutinib 12obinutuzumab 11Cyclophosphamide 9zanubrutinib 8fludarabine 7Magnetic Resonance Spectroscopy 5Bendamustine Hydrochloride 5venetoclax 4Specimen Handling 4Biopsy 4pirtobrutinib 3fludarabine phosphate 3Whole-Body Irradiation 2Vincristine 2Stem Cell Transplantation 2Prednisone 2Mycophenolic Acid 2CT-P10 2Automobiles 2treosulfan 1tafasitamab 1polatuzumab vedotin 1pemigatinib 1loncastuximab tesirine 1ibrutinib 1etoposide phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, B-Cell, Marginal Zone × CT-P10 × Clear all
NCT04840602 2026-06-05

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Recruiting
92 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT06905509 2025-09-29

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

University of California, Davis

Phase 2 Recruiting
25 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡